Please assess the completion status of the following clinical trial:

Trial Title: Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild-moderate chronic kidney disease (glomerular filtration rate \[GFR\] 40-80 mls/min calculated by Cockroft-Gault equation)~* Controlled blood pressure (\< 130/80 mmHg)~* On established (\> 6 weeks) treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).~Exclusion Criteria:~* Diabetes mellitus~* Clinical evidence of fluid overload or hypovolaemia~* Recent (\< 2 months) acute myocardial infarction~* Left ventricular (LV) dysfunction (ejection fraction \< 40% by echocardiography).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: ACTIVE_COMPARATOR): 25mg spironolactone daily
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo medication for the control group

Based on this trial design, predict the completion outcome and termination type (if applicable).